fimaChem: Asia / bile duct cancer recent study

Stock DZ
06.11.2017 kl 13:12

Dette er en arkivert tråd!

a very recent study in Asia (Singapore) (Links below) titled "Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma" also claimed to be largest-ever genomics study of bile duct cancer that identifies distinct subtypes of the cancer.

"The study analyzed genomic and epigenomic molecular data of 489 CCA cases from 10 countries, including Singapore, Thailand and Japan. These 489 cases included both liver fluke-induced (food-borne parasites) CCA and non-liver fluke related CCA. Through analysis of different types of molecular data, the team identified four subtypes, each revealing distinct molecular"

I also find this statement interesting:

“There are no targeted treatments catered for CCA patients, leading to a dismal prognosis. Our study showed that a third of CCA patients may be potentially treated by targeted therapies, including immunotherapy, HER2 inhibitors, or FGFR inhibitors,” said Professor Teh Bin Tean, co-Principal Investigator of the study and Deputy Director (Research) at NCCS. He is Professor of the Cancer & Stem Cell Biology programme at the Duke-NUS Medical School.

Currently, PCI estimates that CCA patients population relevant to fimaChem treatment is less than 1/3? any comments?

may be someone with a medical background can pull more info from the study.


the full study is published under

Redigert 06.11.2017 kl 13:20 Arkivert
06.11.2017 kl 15:21

Merket meg denne konklusjonen

''Clinical trials evaluating targeted therapies in unselected CCA populations have shown minimal benefits.''

Alt ligger til rette for at Pcib m/partner kan ta helle GG markedet i et jafs!
Redigert 06.11.2017 kl 15:22 Arkivert
Arkivert Til toppen